Business Description
Rafael Holdings Inc
NAICS : 531110
SIC : 6519
520 Broad Street, Newark, NJ, USA, 07102
Description
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.98 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.7 | |||||
| Beneish M-Score | -5.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.8 | |||||
| 3-Year EBITDA Growth Rate | -95.8 | |||||
| 3-Year EPS without NRI Growth Rate | -16.9 | |||||
| 3-Year FCF Growth Rate | -68 | |||||
| 3-Year Book Growth Rate | -6.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.26 | |||||
| 9-Day RSI | 62.34 | |||||
| 14-Day RSI | 60.51 | |||||
| 6-1 Month Momentum % | -29.48 | |||||
| 12-1 Month Momentum % | -94.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.51 | |||||
| Quick Ratio | 3.51 | |||||
| Cash Ratio | 3.34 | |||||
| Days Sales Outstanding | 44.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1740.6 | |||||
| Net Margin % | -3322.96 | |||||
| ROE % | -120.49 | |||||
| ROA % | -99.29 | |||||
| ROIC % | -70.27 | |||||
| ROC (Joel Greenblatt) % | -329.91 | |||||
| ROCE % | -124.72 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.24 | |||||
| PB Ratio | 0.46 | |||||
| Price-to-Tangible-Book | 0.49 | |||||
| EV-to-EBIT | -0.06 | |||||
| EV-to-EBITDA | -0.06 | |||||
| EV-to-Revenue | 2.02 | |||||
| EV-to-FCF | -0.6 | |||||
| Price-to-Net-Current-Asset-Value | 0.98 | |||||
| Price-to-Net-Cash | 1.05 | |||||
| Earnings Yield (Greenblatt) % | -1792.89 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:RFL
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.98 | ||
| EPS (TTM) ($) | -7.06 | ||
| Beta | 1.31 | ||
| Volatility % | 70.38 | ||
| 14-Day RSI | 60.51 | ||
| 14-Day ATR ($) | 0.189999 | ||
| 20-Day SMA ($) | 2.1395 | ||
| 12-1 Month Momentum % | -94.89 | ||
| 52-Week Range ($) | 1.6 - 54.83 | ||
| Shares Outstanding (Mil) | 24.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rafael Holdings Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||